Which company first received FDA approval to use CRISPR-Cas9 gene editing technology in a human clinical trial for a therapeutic product?

Gene editing technologies represent one of the most significant scientific product innovations of recent years, revolutionizing research, medicine, and agriculture. CRISPR-Cas9 in particular has transformed how we approach genetic modification, creating new markets and ethical considerations. This poll tests your knowledge about this groundbreaking scientific product's commercial development and its impact on the biotechnology industry.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

CRISPR Therapeutics and Vertex Pharmaceuticals (for CTX001/exa-cel for sickle cell disease)
Editas Medicine (for EDIT-101 for Leber congenital amaurosis)
Intellia Therapeutics (for NTLA-2001 for transthyretin amyloidosis)
Caribou Biosciences (for CB-010 for non-Hodgkin lymphoma)